Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1-BCR-ABL-JAK2 Complex

By Chen Min   Gallipoli Paolo   DeGeer Donna   Sloma Ivan   Forrest Donna L.   Chan Matthew   Lai Damian   Jorgensen Heather   Ringrose Ashley   Wang Hui Mi   Lambie Karen   Nakamoto Helen   Saw Kyi Min   Turhan Ali   Arlinghaus Ralph   Paul James   Stobo Jon   Barnett Michael J.   Eaves Allen   Eaves Connie J   Holyoake Tessa L.   Jiang Xiaoyan  

Journal of the National Cancer Institute, Vol. 105, Iss. 6, 2013-03 ,pp. : 405-423

Oxford University Press

Access to resources Recommend Favorite

Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid

By Zhou Hong-Sheng   Dai Min   Wei Yongqiang   Wang Qiang   Xu Na   Yin Changxin   Meng Fanyi  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1557-1559

Informa Healthcare

Access to resources Recommend Favorite

Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report

By          

Oncology Letters, Vol. 9, Iss. 4, 2015-01 ,pp. : 1957-1961

Spandidos Publications

Access to resources Recommend Favorite

Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylateresistant chronic myeloid leukemia patient

By          

Oncology Letters, Vol. 5, Iss. 5, 2013-01 ,pp. : 1579-1582

Spandidos Publications

Access to resources Recommend Favorite

Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application

By Ghatnekar Ola   Hjalte Frida   Taylor Matthew  

Acta Oncologica, Vol. 49, Iss. 6, 2010-08 ,pp. : 851-858

Informa Healthcare

Access to resources Recommend Favorite